Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | ESRRB | O95718 | 2/20 | 0.36 |
| ▸ | ESRRA | P11474 | 2/20 | 0.36 |
| ▸ | ESRRG | P62508 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046676 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4PDE10AESRRBESRRA | |
| SCHEMBL23602982 | 0.82 | SLC6A2 (0.38) | SLC6A2SLC6A4THRBPDE10AESRRB | |
| SCHEMBL24495118 | 0.77 | CCR2 (0.46) | THRBPDE10ACCR2 | |
| SCHEMBL29365974 | 0.76 | RXFP1 (0.46) | THRBMEN1PDE10AKCNH2 | |
| SCHEMBL22804789 | 0.75 | MEN1 (0.37) | SLC6A2SLC6A4MEN1 | |
| SCHEMBL21876572 | 0.75 | SLC6A2 (0.46) | SLC6A2SLC6A4THRBESRRBESRRA | |
| SCHEMBL24495162 | 0.74 | MEN1 (0.33) | SLC6A2SLC6A4MEN1KCNH2 | |
| SCHEMBL29998338 | 0.73 | ALDH1A1 (0.47) | SLC6A2SLC6A4ESRRBESRRAESRRG | |
| SCHEMBL4592063 | 0.73 | ALDH1A1 (0.54) | — | |
| SCHEMBL21876915 | 0.72 | SLC6A2 (0.49) | SLC6A2SLC6A4THRBESRRBESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993872-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |